Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Overview of Biomarker-Selected Immune Checkpoint Blockade in Lung Cancer (22 mins)
  • CME

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: August 24, 2020 Expiration: August 23, 2021
Start Activity
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Merck Sharp & Dohme Corp.
John L. Marshall, MD
Program Director
Jamie E. Chaft, MD
Scot Niglio, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe recent data on current and emerging biomarkers that predict response to immunotherapy and guide treatment selection across tumor types
  • Discuss the challenges and limitations associated with current and emerging biomarkers including tissue sampling, testing platforms, scoring, and interpretation of results
  • Evaluate evidence on emerging tumor and immune predictive biomarkers and their associated testing platforms
  • Explain the potential benefits of incorporating blood-based or serum-based biomarkers and testing into clinical practice
  • Incorporate expert and guideline recommendations for biomarker testing into clinical practice based on tumor characteristics, using appropriate biopsy sampling and diagnostic testing platforms

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees and fees for non-CME/CE services from Amgen, Bayer, Celgene, Genentech, Merck, and Taiho and salary from Caris and Indivumed.

Faculty

Jamie E. Chaft, MD

Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Jamie E. Chaft, MD, has disclosed that she has received consulting fees and funds for research support (paid to her institution) from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck.
Scot Niglio, MD

Medical Oncologist
Bethesda, Maryland

Scot Niglio, MD, has disclosed that his spouse/partner has received a salary from Stemcell Technologies.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra D. Cravens, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other relevant healthcare and laboratory professionals who treat/manage patients with cancer who are candidates for immunotherapies (including the utility of current and emerging biomarkers to guide cancer treatment with immunotherapies across tumor types).

Goal

The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare providers of immune checkpoint inhibitor therapies so they can confidently and competently integrate these treatments into clinical practice.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 24, 2020, through August 23, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Overview of Biomarker-Selected Immune Checkpoint Blockade in Lung Cancer (22 mins)
  • CME

Learn how to use biomarkers to make optimal immunotherapy selections for patients with lung cancer.
John L. Marshall, MD
Program Director
Jamie E. Chaft, MD
Scot Niglio, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: August 24, 2020 Expiration: August 23, 2021

This program is divided into short segments that you can review from the Activity landing page.

Related Content

In this slideset from Clinical Care Options, Jamie E. Chaft, MD and Kristin Higgins, MD review the role of IO therapy and CRT for early stage NSCLC.

Jamie E. Chaft, MD Kristin Higgins, MD Released: October 23, 2020

Gain key clinical insights fast, with this short slideset from CCO on new biomarkers driving precision care in lung cancer

Edward S. Kim, MD, FACP Sandip P. Patel, MD Released: October 23, 2020

In this slideset from Clinical Care Options, Jamie E. Chaft, MD and Kristin Higgins, MD provides insights on the latest data on IO therapy for lung cancer.

Jamie E. Chaft, MD Kristin Higgins, MD Released: October 23, 2020

Downloadable slideset with key data from the 2020 ESMO Virtual Congress created by Clinical Care Options (CCO)

Yelena Y. Janjigian, MD Joyce O'Shaughnessy, MD Elizabeth R. Plimack, MD, MS person default Vamsidhar Velcheti, MD Released: October 23, 2020

Video Chapters


Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue